Actavis rewrites ‘big pharma’ playbook

Actavis lab

Are big, lean dealmakers running out of targets?

The last bell tolls for the lethal injection

Now pharmaceutical companies shun association with state-sanctioned killing, writes Anjana Ahuja

Drugs groups unite to mine genetic data

Groups to join 100,000 Genomes Project

Venture capitalist Jon Moulton has invested in biotech company RedX Pharma

Moulton-backed RedX Pharma to list on Aim

UK life science industry shows sign of life beyond southeast

Ranbaxy pledges to regain US trust

Sun Pharma wins go-ahead to complete takeover of troubled group

The value of a life is not about cost

Perhaps governments should finance the payment of a national licence fee for drugs

Pharmacyclics boss reaps $3.6bn from bid

AbbVie $21bn takeover delivers almost $4bn to executives

Ebola battle enters ‘dangerous time’

Fresh infection in Liberia underlines challenge of erasing virus

Silicon Valley lands on big pharma’s turf

Drugmakers unsettled as large tech groups turn to healthcare

Apple puts clinical research tool in your pocket

Innovation helps scientists plug in to data from iPhones

Common weedkiller labelled as cancer risk

WHO says Roundup is ‘probable carcinogen’

Cannabis companies: puffed up

Dude, investing in pot is such a drag

Biogen’s Alzheimer’s drug shows early promise

US biotech group’s shares rise 7% after experimental treatment slows rate of cognitive decline

Matching surplus medicine with need

Supply chain management cuts waste in foreign aid

Fund to fight drug-resistant infections

Focus on low and middle-income countries

Dementia research to get $100m boost

Venture capital fund backed by UK ministers and drug companies

Valeant bid knocks Endo out of Salix race

Offer narrowly exceeds cash-and-shares bid from Dublin group

Valeant/Salix: resistance is futile

If Mike Pearson wants to pay more than necessary to clinch a deal, he will encounter little resistance

Valeant raises offer for Salix

Counterbid of $173 a share for drugmaker aims to trump Endo

Tax inversion curb turns tables on US

Over $150bn of inbound cross-border deals announced since crackdown

EDITOR’S CHOICE

Special report

insulin vials ©Jacob Ehrbahn Combating Diabetes

Special report

An elderly man uses a magnifier to see the descriptions on a pack of medicine at a pharmacy in Dandong, Liaoning province March 30, 2011 ©Jacky Chen/Reuter Health: Emerging Markets

COMPANIES NEWS ON TWITTER

More FT Twitter accounts
SHARE THIS QUOTE